Apoptosis News and Research RSS Feed - Apoptosis News and Research

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.
TSRI scientists receive $2.3M to study viruses that cause tropical diseases

TSRI scientists receive $2.3M to study viruses that cause tropical diseases

The outbreak of dengue fever that infected some 20 people in Florida's Martin County late last year unnerved many who feared the tropical disease had once again established a foothold in Florida. The last outbreaks occurred in 2009 and 2010 in Key West—before that, the disease hadn't struck Florida in more than 70 years. [More]
Discovery could lead to new medications for cancer, say Rice University scientists

Discovery could lead to new medications for cancer, say Rice University scientists

A new understanding of proteins at the nexus of a cell's decision to survive or die has implications for researchers who study cancer and age-related diseases, according to biophysicists at the Rice University-based Center for Theoretical Biological Physics. [More]
Proteins that regulate energy metabolism are essential for stem cell formation

Proteins that regulate energy metabolism are essential for stem cell formation

Proteins that regulate energy metabolism are essential for stem cell formation, University of Washington researchers find. [More]
Systemic stem cell therapy reduces malignant mesothelioma growth

Systemic stem cell therapy reduces malignant mesothelioma growth

Systemic delivery of stem cells expressing an apoptosis-inducing protein can successfully incorporate into malignant pleural mesothelioma cells and subsequently induce their death, according to preclinical study findings. [More]
Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML). [More]
Study provides insight into the mechanisms underlying diabetic peripheral neuropathy

Study provides insight into the mechanisms underlying diabetic peripheral neuropathy

Iron overload can lead to cytotoxicity, and it is a risk factor for diabetic peripheral neuropathy. However, the underlying mechanism remains unclear. [More]

Pretreatment with SSTF prevents cerebral ischemia-reperfusion injury, says study

Focal cerebral ischemia-reperfusion may lead to neuronal loss in the hippocampus, which is regarded as one of the basic pathological mechanisms underlying cognitive impairment. [More]

New study shows male hormones play important role; may enhance IVF therapy in women

Several fertility clinics across the country are beginning to administer testosterone, either through a patch or a gel on the skin, to increase the number of eggs produced by certain women undergoing in vitro fertilization (IVF). [More]

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer. [More]

Study identifies promising target for new drugs to treat lethal form of brain cancer

A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. [More]
Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies. [More]
Phasefocus’ KTP associate Dr Suman receives runners up spot for Cellular Heaven and Hell time-lapse video

Phasefocus’ KTP associate Dr Suman receives runners up spot for Cellular Heaven and Hell time-lapse video

Phase Focus Ltd (Phasefocus), the company that is revolutionizing microscopy and imaging with the Phasefocus Virtual Lens® technology, reports on the Celldance competition results held at the recent annual ASCB meeting. KTP associate, Dr Rakesh Suman, was runner up with his video entitled "Cellular Heaven & Hell." [More]
Scientists explain why women with dense breast tissue at greater risk of developing breast cancer

Scientists explain why women with dense breast tissue at greater risk of developing breast cancer

Scientists from The University of Manchester working with IBM Research have identified a key biological mechanism that for the first time explains why women with dense breast tissue are at greater risk of developing breast cancer. [More]
Scientists identify twenty proteins specifically secreted by primary effusion lymphoma cell lines

Scientists identify twenty proteins specifically secreted by primary effusion lymphoma cell lines

​Primary effusion lymphoma (PEL) is a rare B-cell neoplasm distinguished by its tendency to spread along the thin serous membranes that line body cavities without infiltrating or destroying nearby tissue. [More]
Scientists develop new approach to design drugs from genome sequence

Scientists develop new approach to design drugs from genome sequence

In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die. [More]

Researchers discover genetic function that helps "tumor suppressor" genes to prevent cancer

Researchers at Oregon State University have discovered a genetic function that helps one of the most important "tumor suppressor" genes to do its job and prevent cancer. [More]

RNAi-based screening offers MPM treatment hope

Research using RNA interference-based screening has identified several potential targets for the treatment of malignant pleural mesothelioma. [More]

Study points to gender-specific mechanisms of brain repair following oxygen deprivation

Physicians have long known that oxygen deprivation to the brain around the time of birth causes worse damage in boys than girls. Now a study by researchers from the Johns Hopkins Children’s Center conducted in mice reveals one possible reason behind this gender disparity and points to gender-specific mechanisms of brain repair following such injury. [More]

Phasefocus reports on new ptychography paper published in Nature Scientific Reports

... [More]
Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Pfizer Inc. today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer. [More]